Lakefront Biotherapeutics (DE:GXEA)
FRANKFURT:GXEA
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.71Last Year’s EPS
-1.59Same Quarter Last Year
Moderate Sell
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights a major strategic transformation with a high‑profile Ouro/Gilead transaction that brings a promising clinical asset (gamgertamig) and unlocks substantial financial flexibility. Operationally, the company reported meaningful quarterly improvement in operating loss and a net profit driven by financial gains, maintained a strong cash position, and emphasized cost discipline and capital‑efficient development plans. Offsetting these positives are a very large near‑term cash deployment (upfront and wind‑down costs), a steep YoY revenue decline driven by prior‑year accounting recognition, continued operating losses, and clinical and competitive risks inherent to the BCMA/CD3 space. On balance, the strategic upside and improved reported results outweigh the near‑term financial outflows and risks.Company Guidance
Strategic Partnership and Acquisition (Ouro/Gilead)
Entered into a binding agreement with Gilead for the Ouro Medicines portfolio, centered on gamgertamig (BCMA/CD3 T‑cell engager). Transaction includes an upfront payment of approximately EUR 713 million and adds 3 preclinical programs. The deal also includes a partial waiver/modification of legacy OLCA terms enhancing strategic flexibility.
Promising Clinical Profile for gamgertamig
Clinical experience in >60 patients across 5 autoimmune indications showed rapid induction of durable complete responses, minimal cytokine release syndrome (CRS) with current schedule and consistent results across indications. Program has Fast Track and Orphan Drug designations (U.S.) for ITP and AHA and may enter registrational studies as early as 2027; management cites potential to address 20+ indications.
Material Financial Flexibility Unlocked
Modification of OLCA unlocked a EUR-denominated $500 million-equivalent bucket for broader use beyond Ouro, with up to $150 million available for return of capital subject to limits. Share repurchase authorization was approved by shareholders, with repurchase details to be provided after transaction close.
Substantial Improvement in Reported Results
Operating loss improved to EUR 63.7 million in Q1 2026 from EUR 158.7 million in Q1 2025 (an improvement of EUR 95.0 million, ~60% improvement in operating loss). Net financial income of EUR 77.7 million (driven by EUR 64.3 million unrealized FX/fair value gains) contributed to a net profit of EUR 14.5 million vs a net loss of EUR 153.4 million in Q1 2025 (swing of EUR 167.9 million).
Robust Cash & Investments Position
Financial investments and cash & cash equivalents totaled EUR 2,982.2 million as of March 31, 2026. Management expects year-end cash of EUR 1.975 billion to EUR 2.05 billion after Ouro-related and wind-down expenditures and states the company will remain robustly funded with majority of cash available for additional strategic transactions.
Operating Cost Reductions and R&D Discipline
R&D expenses decreased to EUR 31 million in Q1 2026 driven by lower severance and absence of prior-year restructuring charges, contributing to an improved cost base and lower operating losses.
Corporate Transformation and Rebrand
Completed major management and Board changes, appointed Gino Santini as new Board Chair, and announced a corporate name change to Lakefront Biotherapeutics (expected ticker LKFT on Euronext and NASDAQ), signaling strategic repositioning.
Capital‑Efficient Clinical Development Pathway
Management emphasized that initial indications for gamgertamig are orphan/rare diseases with relatively small, manageable registrational trials given the magnitude of observed effect, enabling speed‑to‑market and capital efficiency.
DE:GXEA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:GXEA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | €24.40 | €24.00 | -1.64% |
Feb 23, 2026 | €28.40 | €28.60 | +0.70% |
Nov 05, 2025 | €26.40 | €26.20 | -0.76% |
Jul 23, 2025 | €27.80 | €28.00 | +0.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lakefront Biotherapeutics (DE:GXEA) report earnings?
Lakefront Biotherapeutics (DE:GXEA) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is Lakefront Biotherapeutics (DE:GXEA) earnings time?
Lakefront Biotherapeutics (DE:GXEA) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Lakefront Biotherapeutics stock?
The P/E ratio of Lakefront Biotherapeutics is N/A.
What is DE:GXEA EPS forecast?
DE:GXEA EPS forecast for the fiscal quarter 2026 (Q2) is -0.71.